Arrien Pharmaceuticals is a clinical stage drug discovery company based in Bridgeport, CT. They specialize in developing small molecules that target protein kinase signaling, nuclear hormone receptor, and immuno-oncology checkpoint pathway targets for the treatment of human cancers, autoimmune, and neurodegenerative diseases. With their proprietary platform technology, they have successfully discovered two clinical candidates and have several others in development.
Their pipeline includes SLX-0528 (previously known as XT-0528), BOS-172767, ARN-6039, ARN-3261 (now called GRN300), ARN-0953, and ARN-4079 (now called OR-101). Arrien Pharmaceuticals has partnered with various companies for the development and licensing of their clinical candidates, and they continue to accelerate innovation through smart drug design to target medicines for improved patient outcomes.
Generated from the website